Literature DB >> 16239908

Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.

M Okamoto, A Okano, S Akamatsu, E Ashihara, T Inaba, H Takenaka, N Katoh, S Kishimoto, C Shimazaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16239908     DOI： 10.1038/sj.leu.2403996

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  32 in total

Review 1.  The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  Elizabeth Naparstek
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

2.  Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.

Authors:  James S Young; Tao Wu; Yuhong Chen; Dongchang Zhao; Hongjun Liu; Tangsheng Yi; Heather Johnston; Jeremy Racine; Xiaofan Li; Audrey Wang; Ivan Todorov; Defu Zeng
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

3.  Rituximab: a review of dermatological applications.

Authors:  Jason J Emer; Wolinsky Claire
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

4.  Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.

Authors:  Z DeFilipp; M Purcell; W A C Harris; D J Chandra; C Gleason; J Wrammert; S Sarantopoulos; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

Review 5.  Oral graft-versus-host disease.

Authors:  M M Imanguli; I Alevizos; R Brown; S Z Pavletic; J C Atkinson
Journal:  Oral Dis       Date:  2008-07       Impact factor: 3.511

Review 6.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

7.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

8.  Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?

Authors:  Stefan Deneberg; Richard Lerner; Per Ljungman; Olle Ringden; Hans Hägglund
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 9.  Diagnosis and Management of Systemic Sclerosis: A Practical Approach.

Authors:  Jason J Lee; Janet E Pope
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.